In this week's Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.
Read More »Lactobacillus reuteri Improves Incretin and Insulin Secretion
Probiotic does not change insulin sensitivity in glucose-tolerant individuals.
Read More »Dr. Paresh Dandona, Part 1: GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes
Dr. Paresh Dandona, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Buffalo, The State University of New York, joins Associate Medical Editor Joy Pape in a discussion at the 2015 ADA Sessions in Boston regarding highlights of his presentation, "GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes."
Read More »Diabetes Medication May Be Used In Treating Alcohol Dependence
Liraglutide use led to less alcohol intake and suppressed dopamine effects in rodents.
Read More »Fasting Until Noon Increases Postprandial Glucose Levels, Impaired Insulin Response After Lunch and Dinner
Breakfast consumption led to a reverse metabolic state in individuals with type 2 diabetes.
Read More »Can Smaller Forks Help Diabetes Patients?
Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased...
Read More »Chronically Elevated TNFα Level in Obese Patients Impairs Secretion of GLP-1
Anti-TNFα biologics might help to enhance GLP-1 secretion.
Read More »Increase in Osteoporosis Thought Due to Increase in DPP-4
Postmenopausal women with normal glucose tolerance focus of study.
Read More »GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Data establishes effectiveness of semaglutide in treatment of type 2 diabetes…. Novo Nordisk is currently the manufacturer for Victoza (liraglutide), a GLP-1 agonist that needs to be injected once daily. However, semaglutide only needed to be taken once weekly, which is more preferred. The main objective of the SUSTAIN-3 trial …
Read More »GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
A new study shows liraglutide mitigates the bone loss common with low calorie diets… Weight loss is frequently tied to reduced bone mass in adults who embark on a low calorie diet, putting them at increased risk of fractures following significant weight reduction. Furthermore, the reduction in bone mass does …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.